Please assess the completion status of the following clinical trial:

Trial Title: Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, between the ages of 18 and 80 years at the time of screening.~* Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questions and follow instructions during fMRI assessments and aiTBS interventions~* Stated willingness to adhere to all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information~* Primary diagnosis of Bipolar I or II Disorder according to the Diagnosis and Statistical Manual of Mental Disorders, 5th edition (DSM-5)~* Currently experiencing a hypomanic or manic episode according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, 5th edition (DSM-5)~* YMRS score of ≥12 at screening.~* Access to ongoing psychiatric care after completion of the study.~* Must be adherent or agreeable to pharmacotherapy per clinical standard of care at screening.~* Patients who are in both voluntary and involuntary hold.~* In good general health, as evidenced by medical history.~* For females of reproductive potential: use of highly effective contraception.~Exclusion Criteria:~* Currently pregnant or breastfeeding.~* Primary psychiatric condition other than Bipolar I or II Disorder requiring treatment other than stable comorbid anxiety disorder.~* Diagnosis of Intellectual Disability or Autism Spectrum Disorder~* Current moderate or severe substance use disorder or demonstrating signs of acute substance intoxication or withdrawal~* Active suicidal ideation (defined as an M-SSI \> 8)~* History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma~* Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)~* Contraindication to MRI (e.g. ferromagnetic metal in their body)~* Treatment with another investigational drug or other intervention within the study period~* Any other condition deemed by the PI to interfere with the study or increase risk to the participant~* Current unmanageable psychosis that the PI believes would interfere with treatment~* Any history of psychosurgery~* Depth-adjusted aiTBS treatment dose \> 65% maximum stimulator output (MSO).~* Any other condition deemed by the PI to interfere with the study or increase risk to the participant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Right DLPFC aiTBS stimulation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues